

# PATENT COOPERATION TREA

# **PCT**

#### INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference S-30287/A	FOR FURTHER See Notification (Form PCT/ISA/	of Transmittal of International Search Report 220) as well as, where applicable, item 5 below.
nternational application No.	International filing date (day/month/year)	(Earliest) Priority Date (day/month/year)
PCT/EP 98/07792	01/12/1998	03/12/1997
Applicant		
NOVARTIS AG et al.		
This International Search Report has according to Article 18. A copy is being	been prepared by this International Searching Aug g transmitted to the International Bureau.	thority and is transmitted to the applicant
This International Search Report cons	ists of a total of sheets.  If by a copy of each prior art document cited in this	s report.
Basis of the report     With regard to the language, language in which it was filed	the international search was carried out on the ba unless otherwise indicated under this item.	asis of the international application in the
the international search	ch was carried out on the basis of a translation of	the international application furnished to this
b. With regard to any nucleotide was carried out on the basis of	e and/or amino acid sequence disclosed in the i	international application, the international search
langed .	international application in computer readable for	rm.
	dy to this Authority in written form.	
<u></u>	dy to this Authority in computer readble form.	
the statement that the	e subsequently furnished written sequence listing on as filed has been furnished.	does not go beyond the disclosure in the
the statement that the furnished	information recorded in computer readable form	is identical to the written sequence listing has bee
2. Certain claims were	found unsearchable (See Box I).	
3. Unity of invention is	lacking (see Box II).	
4. With regard to the title,		
X the text is approved a	s submitted by the applicant.	
the text has been est	ablished by this Authority to read as follows:	
·		
5. With regard to the abstract,		•
the text has been est	is submitted by the applicant. ablished, according to Rule 38.2(b), by this Author n the date of mailing of this international search re	rity as it appears in Box III. The applicant may, aport, submit comments to this Authority.
6. The figure of the drawings to be	published with the abstract is Figure No.	
as suggested by the	applicant.	None of the figures.
because the applican	t failed to suggest a figure.	
	etter characterizes the invention.	

09/554,941 Exhibit A

Form PCT/ISA/210 (first sheet) (July 1998)

## **INTERNATIONAL SEARCH REPORT**

International Application No PCT/EP 98/07792

A. CLASSIFICATION OF SUBJECT MATTER IPC 6 C12N15/82 C12N15/52 C12N5/10

G01N33/50

C12N15/53 A01H5/00

C12N9/00

C12N9/02

According to International Patent Classification (IPC) or to both national classification and IPC

#### B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N


Documentation searched other than minimum documentation to the extent that such documents are included. In the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUM	ENTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to daim No.
. <b>X</b>	WO 96 10083 A (CIBA GEIGY AG) 4 April 1996 page 3,6; example 22	1,2,7, 13,15-17
X	EP 0 497 366 A (DONEGANI GUIDO IST) 5 August 1992 pages 5,6-15,16; page 18, line 43-50; claims	1,2,8, 13,15-17
Υ	WO 96 16173 A (UNIV LEEDS ;ATKINSON HOWARD JOHN (GB); MCPHERSON MICHAEL JOHN (GB)) 30 May 1996 pages 1,3,4,5,; page 6, line 16-20; page 11,22-30; claims 27-38; Table 3	1-4,7, 12-17

Y Further documents are listed in the continuation of box C.	Patent family members are listed in annex.
"Special categories of cited documents:  "A" document defining the general state of the art which is not considered to be of particular relevance  "E" earlier document but published on or after the international filing date  "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  "O" document referring to an oral disclosure, use, exhibition or other means  "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone  "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.  "&" document member of the same patent family
Date of the actual completion of the international search	Date of mailing of the international search report
25 March 1999	13/04/1999
Name and mailing address of the ISA  European Patent Office, P.B. 5818 Patentlaan 2  NL - 2280 HV Rijswijk  Tel. (+31-70) 340-2040, Tx. 31 651 epo ni, Fax: (+31-70) 340-3016	Authorized officer  Holtorf, S
Pax. (+31-70) 3+0-3010	

1



Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 94 13810 A (UNIV MELBOURNE ;ANDERSON MARILYN ANNE (AU); ATKINSON ANGELA HILARY) 23 June 1994	1-3,7, 13-17
Y	see page 4	1-4,6,7, 12-17
Y	WO 97 20057 A (NICKERSON BIOCEM LTD; ATKINSON HOWARD JOHN (GB); LILLEY CATHERINE) 5 June 1997 page 7,8,11; example 3,4,5; claims	6
A	WO 92 15690 A (NICKERSON BIOCEM LTD) 17 September 1992 pages 6,7,9,10; examples 1,6	1-17
A	LILLEY,C.J., ET AL.: "characterization of intestinally active proteinases of cyst nematodes" PARASITOLOGY, vol. 113, no. Pt4, October 1996, pages 415-425, XP002097967 abstract; page 416,417,420,423, left column	1-17
<b>A</b>	URWIN P E ET AL: "RESISTANCE TO BOTH CYST AND ROOT-KNOT NEMATODES CONFERRED BY TRANSGENIC ARABIDOPSIS EXPRESSING A MODIFIED PLANT CYSTATIN" PLANT JOURNAL, vol. 12, no. 2, 1997, pages 455-461, XP000198746 page 459, right column	1-17
Ρ,Χ	URWIN, P.E., ET AL.: "enhanced transgenic plant resistance to nematodes by dual proteinase inhibitor constructs" PLANTA, vol. 204, April 1998, pages 472-479, XP002097968 see the whole document	1-10,12, 13,15-17

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No CT/EP 98/07792

Patent document cited in search repo		Publication date		Patent family member(s)	Publication date
WO 9610083.	A	04-04-1996	US	5849870 A	15-12-1998
MO 9010003.	^	04 04 1330	ĂŬ	692934 E	
			AU	3743395 A	
			BG	101384	
			BR	9509099	
	•		CA	2199049 <i>F</i>	
			CN	1160420	
		•	EP	0792363 A	
			HU	77449 <i>F</i>	
			JP	10506532	
			US	5872212 A	
			US	5770696 A	
			US	5840868 A	
		•	US	5866326 <i>F</i>	
•			US	5877012	
			ZA	9508121	29-04-1996
EP 0497366	Α	05-08-1992	AU	648140 E	
			AU	1065092 A	\ 06-08-1992
			CA	2060455 A	02-08-1992
			JP	5294995 A	09-11-1993
			US	5519115 /	21-05-1996
WO 9616173	A	30-05-1996	AU	3877095 <i>l</i>	17-06-1996
	••		CA	2205356	
			EP	0793722	
			JP	10510146	06-10-1998
WO 9413810	Α	23-06-1994	. AU	680855 E	3 14-08-19 <b>97</b>
	••		AU	5689194	
			CA	2151933 /	
			EP	0674712 /	
			JP	8506482	
		•	NZ	258824 /	
WO 9720057	A	05-06-1997	AU	7702496 /	19-06-1997
no 3/2003/	^	00 00 1777	CA	2238943	
			EP	0871752	
WO 9215690	A	17-09-1992	AT	160175	 Г 15-11-1997
MO 3213030	^	11 03 1332	ÂÙ	665530 I	
			AU	1353192	
			CA	2107234	
			DE	69223080	
			DE	69223080	
			EP EP	0502730	
		•		2111041	
			ES	3026133	
			GR		
			US	5494813	4 61-02-1990

PATENT COOPERA ARY EXAMINING AUTHORITY INTERNA 16 To: Becker, Konrad **NOVARTIS AG** Corporate Intellectual Property Patent & Trademan Dept. WRITTEN OPINION CH-4002 Basel (PCT Rule 66) SUISSE 18.0kt. 1999 Date of mailing 12.10.99 (day/month/year) Kopien: within 3 month(s) **REPLY DUE** Applicant's or agent's file reference from the above date of mailing S-30287/A Priority date (day/month/year) International filing date (day/month/year) International application No. 03/12/1997 01/12/1998 PCT/EP98/07792 International Patent Classification (IPC) or both national classification and IPC C12N15/82 Applicant NOVARTIS AG et al. This written opinion is the first drawn up by this International Preliminary Examining Authority. This opinion contains indications relating to the following items: Basis of the opinion ☐ Priority ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability III ☐ Lack of unity of invention Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement V١ Certain document cited ☐ Certain defects in the international application VII ☑ Certain observations on the international application VIII The applicant is hereby invited to reply to this opinion. See the time limit indicated above. The applicant may, before the expiration of that time limit, When? request this Authority to grant an extension, see Rule 66.2(d). By submitting a written reply, accompanied, where appropriate, by amendments, according to Rule 66.3. How? For the form and the language of the amendments, see Rules 66.8 and 66.9. For an additional opportunity to submit amendments, see Rule 66.4. Also: For the examiner's obligation to consider amendments and/or arguments, see Rule 66.4 bis. For an informal communication with the examiner, see Rule 66.6. If no reply is filed, the international preliminary examination report will be established on the basis of this opinion. The final date by which the international preliminary examination report must be established according to Rule 69.2 is: 03/04/2000. Authorized officer / Examiner Name and mailing address of the international

09/554,941 Exhibit B

preliminary examining authority:

**European Patent Office** D-80298 Munich

Tel. +49 89 2399 - 0 Tx: 523656 epmu d

Fax: +49 89 2399 - 4465

Merlos-Lange, A.M.

Formalities officer (incl. extension of time limits)

Telephone No. +49 89 2399 8061



#### WRITTEN OPINION

I. B	asis	of	the	opin	ion
------	------	----	-----	------	-----

1.	This opinion has been drawn on the basis of (substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this opinion as "originally filed".):				
	Description, pages:				
	1-32	as originally filed			
	Claims, No.:				
	1-17	as originally filed			

☐ the claims, Nos.:☐ the drawings, sheets:

2. The amendments have resulted in the cancellation of:

- 3. This opinion has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):
- 4. Additional observations, if necessary:
- V. Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- 1. Statement

Novelty (N) Claims see sep. sheet

Inventive step (IS) Claims see sep. sheet

Industrial applicability (IA) Claims

2. Citations and explanations

see separate sheet

### WRITTEN OPINION

### VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

see separate sheet

1.1 With respect to document WO 96/10083, claims 1, 2, 7, 13 and 15-17 appear not to conform with the requirements of Art. 33(2), (3) PCT. Said document describes the recombinant production of fusion proteins optionally linked by a linker region for the purpose of protecting plants against insect pests (see pages 3 and 4, 6 and 7, Example 22 and part of the claims).

Alternatively, with respect to documents EP-0 497 366 and WO 94/13810, it would appear that claims 1, 2, 3, 6, 7, 8 and 12-17 do not refer to novel and inventive matter.

WO 94/13810 discloses the construction of proteinase inhibitor fusion proteins linked via a protease sensitive linker so that upon expression in a plant transformed with said construct, the plant proteinases cleave the fusion molecule. The fusion protein should increase, enhance or facilitate in plants, the resistance to insects or other pathogens.

Document EP-A-0 497 366 describes the construction of so-called "bridged" oligopeptides to protect plants against microbial pathogens (see page 5, last paragraph, page 7, 16-21).

At present, the above cited claims are too generally drafted and lack any particular features which would impart novelty and/or inventiveness to the subject-matter claimed.

- 1.2 It is further noted that document WO 96/16173 refers to the development of modified and thus more effective proteinase inhibitors such as Oc-IdeltaD86 to make plants nematode-resistant. The use of such proteinase inhibitors in the method as claimed in claims 1-4, 7 and 12-17 therefore appears obvious and thus not inventive (Art. 33(3) PCT).
- Having regard to claim 5, it is unclear whether the used proteinase inhibitor CpTI 2). is commonly known and made available to the public (Art. 5 and 6 PCT).

The expression "preferentially" used in claim 6 raises unclarity whether the promoter is root-specific or not.



# **PCT**

### INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference S-30287/A			ation of Transmittal of International Examination Report (Form PCT/IPEA/416)				
International application No.	International filing date (day/month/ye	ar)	Priority date (day/month/year)				
PCT/EP98/07792	01/12/1998		03/12/1997				
International Patent Classification (IPC) or nat C12N15/82  Applicant	tional dassification and IPC						
NOVARTIS AG et al.							
This international preliminary exami and is transmitted to the applicant a		y this Inte	rnational Preliminary Examining Authority				
2. This REPORT consists of a total of	5 sheets, including this cover shee	et.					
been amended and are the bas (see Rule 70.16 and Section 60	This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT). These annexes consist of a total of sheets.						
3. This report contains indications rela	ting to the following items:						
l ⊠ Basis of the report							
II 🗆 Priority							
III   Non-establishment of o	pinion with regard to novelty, inven	tive step	and industrial applicability				
IV 🛛 Lack of unity of invention							
V ☒ Reasoned statement ur citations and explanatio	nder Article 35(2) with regard to no ons suporting such statement	velty, inve	entive step or industrial applicability;				
VI 🖾 Certain documents cite							
VII			·				
VIII ⊠ Certain observations or	n the international application						

09/554,941 Exhibit C Name and mailing address of the international preliminary examining authority:

European Patent Office
D-80298 Munich
Tel. +49 89 2399 - 0 Tx: 523656 epmu d

Date of submission of the demand

Authorized officer

A. M. Merlos

Telephone No. +49 89 2399 8559

Date of completion of this report

27. 03.00



Fax: +49 89 2399 - 4465

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/EP98/07792

l. Basis	of	the	repo	rt
----------	----	-----	------	----

1. This report has been drawn on the basis of (substitute sheets which have been furr response to an invitation under Article 14 are referred to in this report as "originally							ed to the	receivin not an	g Office in	
	the report since they do not contain amendments.):									
	Description, pages:									
	1-32	as originally	filed							
	Claims, No.:									
	1-17	as originally	filed	·						
2.	The amendments have	e resulted in th	ne cancel	lation of:						
	☐ the description,	pages:								
	☐ the claims,	Nos.:								
	☐ the drawings,	sheets:								
3.	☐ This report has be considered to go t	en establishe peyond the dis	d as if (sesciosure	ome of) the amendmeas filed (Rule 70.2(c)	ents had no	ot been m	ade, since	e they h	ave been	
4.	Additional observation	s, if necessar	y:							
٧	. Reasoned statement applicability; citation	under Article s and explan	e 35(2) w ations s	ith regard to novelt upporting such stat	y, inventive ement	e step or	industria	ıl		
1.	Statement	·							2	
	Novelty (N)	Yes: No:		4, 5, 6, 9-11 1, 2, 3, 7, 8, 12-17						
	Inventive step (IS)	Yes: No:	Claims Claims	9-11 1-8, 12-17						
	Industrial applicability	(IA) Yes: No:	Claims Claims	1-17						

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/EP98/07792

2. Citations and explanations

see separate sheet

#### VI. Certain documents cited

1. Certain published documents (Rule 70.10)

and / or

2. Non-written disclosures (Rule 70.9)

see separate sheet

#### VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

see separate sheet

1.1 With respect to document WO 96/10083, claims 1, 2, 7, 13 and 15-17 appear not to conform with the requirements of Art. 33(2), (3) PCT. Said document describes the recombinant production of fusion proteins optionally linked by a linker region for the purpose of protecting plants against insect pests (see pages 3 and 4, 6 and 7, in particular Example 22 and part of the claims).

Alternatively, with respect to documents EP-0 497 366 and WO 94/13810, it would appear that claims 1, 2, 3, 6, 7, 8 and 12-17 do not refer to novel and/or inventive subject-matter.

WO 94/13810 discloses the construction of proteinase inhibitor fusion proteins linked via a protease sensitive linker so that upon expression in a plant transformed with said construct, the plant proteinases cleave the fusion molecule. The fusion protein should increase, enhance or facilitate in plants, the resistance to insects or other pathogens (see page 8, line 15 to page 12, line 31, claims) Document EP-A-0 497 366 describes the construction of so-called "bridged" oligopeptides to protect plants against microbial pathogens (see page 5, last paragraph, pages 7 and 16-21).

At present, claims 1-3, 6-8, and 12-17 are too generally drafted and lack any particular features which would render the matter claimed clearly novel and/or inventive with respect to the prior art.

- 1.2 It is further noted that document WO 96/16173 refers to the development of modified and/or hybrid proteinase inhibitors which are more effective in making plants nematode-resistant. The use of such hybrid proteinase inhibitors in the method as claimed in claims 1-4, 7, 12 and 17, the fusion proteins and transgenic plants expressing them and the corresponding DNA molecules encoding these hybrids (claims 13-16) therefore appear obvious. Said claims are therefore regarded to lack an inventive aspect according to (Art. 33(3) PCT). This is also true for claim 5 wherein the method particularly refers to CpTI, insofar as the cowpea trypsin inhibitor (CpTI) was already known to have anti-nematode activity (see WO92/15690).
- 2). The expression "preferentially" used in claim 6 raises unclarity whether the claim is limited to a root-specific promoter or not.
- 3). In case of an unvalid priority of 03.12.1997, intermediate document "Urwin et al., Planta, vol. 204, April 1998, pages 472-479" may become relevant when the

# INTERNATIONAL PRELIMINARY International application No. PCT/EP98/07792 EXAMINATION REPORT - SEPARATE SHEET

application enters the european phase.